This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Schizophrenia
  • /
  • Cariprazine: A Review in Schizophrenia.
Journal

Cariprazine: A Review in Schizophrenia.

Read time: 1 mins
Published:1st Jun 2017
Author: Garnock-Jones KP.
Source: CNS Drugs
Availability: Pay for access, or by subscription
Ref.:CNS Drugs. 2017;31(6):513-525.
DOI:10.1007/s40263-017-0442-z

Cariprazine (Vraylar™) is a dopamine D3-preferring D2/D3 receptor partial agonist indicated for the treatment of patients with schizophrenia. This narrative review summarizes pharmacological, efficacy and tolerability data relevant to the use of cariprazine in patients with this disorder. In 6-week, phase IIb and III trials in patients with schizophrenia, cariprazine was significantly more efficacious than placebo in improving schizophrenia symptoms, including improvements in Positive and Negative Syndrome Scale (PANSS) total scores.

It was associated with a significantly longer time to relapse than placebo in a long-term, phase III, relapse-prevention study. Cariprazine was also significantly more efficacious than risperidone in improving PANSS Factor Score for Negative Symptoms in a phase III trial in patients with predominantly negative symptoms of schizophrenia, a typically difficult to treat group of patients. Cariprazine was generally well tolerated in clinical trials, with most adverse events being of mild to moderate severity, and metabolic changes observed were considered generally not clinically significant. Cariprazine is a useful addition to the treatment options for schizophrenia, and may be of particular use in patients with predominantly negative symptoms.

 

Read abstract on library site

Access full article